Penserra Capital Management LLC Akebia Therapeutics, Inc. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$2.26 - $3.34 $9,028 - $13,343	-3,995 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $822 - $1,358	350 Added 9.6%	3,995 $11,000
Q2 2021 Aug 12, 2021	BUY	$2.83 - $4.2 $466 - $693	165 Added 4.74%	3,645 $13,000
Q1 2021 May 13, 2021	BUY	$2.92 - $5.06 $467 - $809	160 Added 4.82%	3,480 $11,000
Q4 2020 Feb 12, 2021	BUY	$2.22 - $3.78 $4,662 - $7,938	2,100 Added 172.13%	3,320 $9,000
Q3 2020 Nov 13, 2020	BUY	$2.39 - $13.08 $2,915 - $15,957	1,220 New	1,220 $3,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.